Related Experiment Videos
In-vitro susceptibility of Pseudomonas species to fifteen antimicrobial agents
Abstract:
The in-vitro susceptibility of four Pseudomonas spp. (P. aeruginosa, P. fluorescens, P. maltophilia and P. putida) to 15 antimicrobials was determined. Ciprofloxacin had the greatest in-vitro activity. Although the susceptibility of the different species to individual agents was quite variable, they tended to be less susceptible to agents such as amikacin, aztreonam, cefoperazone, ceftazidime and piperacillin, already in clinical use at our institution, than to newer agents, not currently in clinical use.
Insights
Ciprofloxacin showed the highest in-vitro activity against Pseudomonas species. Susceptibility varied, with less susceptibility to older, clinically used antimicrobials compared to newer agents.
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Pseudomonas species are opportunistic pathogens.
- Understanding their antimicrobial susceptibility is crucial for effective treatment.
- Current clinical practices may influence observed resistance patterns.
Purpose of the Study:
- To determine the in-vitro susceptibility of four Pseudomonas species to 15 antimicrobials.
- To compare the activity of clinically used agents versus newer agents.
- To identify potential treatment options for Pseudomonas infections.
Main Methods:
- In-vitro susceptibility testing of four Pseudomonas species (P. aeruginosa, P. fluorescens, P. maltophilia, P. putida).
- Testing against a panel of 15 different antimicrobial agents.
- Comparative analysis of susceptibility data.
Main Results:
- Ciprofloxacin demonstrated the greatest in-vitro activity against the tested Pseudomonas species.
- Significant variability in susceptibility was observed across different species and agents.
- Pseudomonas isolates were generally less susceptible to amikacin, aztreonam, cefoperazone, ceftazidime, and piperacillin compared to newer agents.
Conclusions:
- Ciprofloxacin is a promising agent for treating infections caused by these Pseudomonas species.
- Novel antimicrobial agents may offer better efficacy than older, established drugs.
- Antimicrobial stewardship is essential, considering the variable susceptibility profiles.